# A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma

> **NCT07740993** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Sebaceous Gland Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** disitamab vedotin

## Key facts

- **NCT ID:** NCT07740993
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07740993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07740993, "A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07740993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*